US Federal 2025-2026 Regular Session

US Federal House Bill HB5133

Introduced
9/4/25  

Caption

Patients’ Right to Know Their Medication Act of 2025

Impact

The proposed regulations will require that all prescription drugs come with a standardized printed medication information document, enhancing transparency and fostering better understanding among patients. This paper document must convey essential details such as indications for use, contraindications, warnings, and directions for use in plain language, thereby aiming to mitigate risks associated with adverse drug events. Financially, the legislation also promises potential savings in healthcare costs by reducing the occurrences of emergency room visits related to medication mishaps, which are estimated to save billions annually.

Summary

House Bill 5133, titled the ''Patients’ Right to Know Their Medication Act of 2025'', aims to amend the Federal Food, Drug, and Cosmetic Act concerning the patient medication information required on prescription drug labels. The bill emphasizes the need for standardized, comprehensible, and accessible medication information, advocating that a well-formulated patient medication information (PMI) will significantly enhance patient safety and understanding. The rationale is supported by the fact that many patients may encounter difficulties accessing electronic versions of medication information, highlighting the necessity for a paper option.

Contention

A significant point of contention lies in the requirement for manufacturers to adhere to these new standards. Supporters of the bill argue that the enhanced labeling will benefit patient awareness and medication adherence, potentially leading to improved healthcare outcomes. Critics, however, might express concerns regarding the burden placed on pharmaceutical companies to comply with the new labeling requirements, possibly increasing costs that could affect drug pricing in a broader economic context. Additionally, the time frame of one year for implementing these changes may also invite debate over the feasibility of rapid compliance.

Final_notes

Overall, HB 5133 represents a pivotal shift in how prescription medication information is disseminated to the public, reinforcing the importance of patient rights to access clear and effective medication information. As discussions on this bill progress, stakeholders will need to consider its implications not only on patient safety but also on the pharmaceutical industry and healthcare economics.

Companion Bills

No companion bills found.

Previously Filed As

US HB3472

OPIOID PATIENTS RIGHT TO KNOW

US SB104

To Amend The Arkansas Pharmacy Benefits Manager Licensure Act; To Protect Patients' Rights And Access To Medications; And To Declare An Emergency.

US HB2471

Right Drug Dose Now Act of 2025

US HB2537

Relating To The Patients' Bill Of Rights.

US SB3027

Relating To The Patients' Bill Of Rights.

US HB2092

SPEAK Act of 2025 Supporting Patient Education And Knowledge Act of 2025

US HB1600

Health care; Lori Brand Patient Bill of Rights Act of 2025; rights of patient; responsibilities of patients; rights of minors; responsibilities of parents; effective date.

US HB1600

Health care; Lori Brand Patient Bill of Rights Act of 2025; rights of patient; responsibilities of patients; rights of minors; responsibilities of parents; effective date.

US HB5316

Drug Shortage Compounding Patient Access Act of 2025

US HB2694

Enacting the opioid patients right to know act to require the disclosure of the risks associated with prescribed opioid use.

Similar Bills

No similar bills found.